Comparing antibody and small-molecule therapies for cancer

被引:623
作者
Imai, Kohzoh
Takaoka, Akinori
机构
[1] Sapporo Med Univ, Chuo Ku, Sapporo, Hokkaido 0608556, Japan
[2] Univ Tokyo, Fac Med, Grad Sch Med, Dept Immunol,Bunkyo Ku, Tokyo 1130033, Japan
关键词
D O I
10.1038/nrc1913
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-molecule compounds have been approved for cancer treatment. Both antibodies and small-molecule compounds are therefore promising tools for target-protein-based cancer therapy. We discuss and compare the distinctive properties of these two therapeutic strategies so as to provide a better view for the development of new drugs and the future direction of cancer therapy.
引用
收藏
页码:714 / 727
页数:14
相关论文
共 163 条
[1]   Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer [J].
Agus, DB ;
Gordon, MS ;
Taylor, C ;
Natale, RB ;
Karlan, B ;
Mendelson, DS ;
Press, MF ;
Allison, DE ;
Sliwkowski, MX ;
Lieberman, G ;
Kelsey, SM ;
Fyfe, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2534-2543
[2]  
Amann J, 2005, CANCER RES, V65, P226
[3]  
[Anonymous], NAT REV DRUG DISC SU
[4]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[5]  
Arteaga CL, 2003, CLIN CANCER RES, V9, P1579
[6]  
Bailey L. Renee, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1362
[7]   Upping the ante on antibodies [J].
Baker, M .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1065-1072
[8]   Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].
Baselga, J ;
Pfister, D ;
Cooper, MR ;
Cohen, R ;
Burtness, B ;
Bos, M ;
D'Andrea, G ;
Seidman, A ;
Norton, L ;
Gunnett, K ;
Falcey, J ;
Anderson, V ;
Waksal, H ;
Mendelsohn, J .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914
[9]  
Baselga J, 2001, EUR J CANCER, V37, pS16
[10]  
Baselga J, 1998, CANCER RES, V58, P2825